20 results about "In vitro growth" patented technology

The invention discloses application of a yncJ gene in regulation and control of toxicity of salmonella typhimurium, and belongs to the technical field of biology. According to the invention, the function of the yncJ gene is studied by constructing the yncJ gene deleted strain of salmonella typhimurium, and it is found that after the yncJ gene is deleted, the multiplication capacity of the strain in macrophages is significantly reduced; infected mouse experiments show that the lethal ability of the yncJ gene deleted strain to mice is remarkably reduced. Moreover, the conventional biochemical characteristics and the in-vitro growth speed of the yncJ gene deletion strain are not obviously changed, so that the yncJ gene deletion strain has an application prospect in production of attenuated vaccines for preventing and treating salmonella typhimurium.

The invention discloses a toxoplasma gondii attenuated strain with deletion of a Tgsrs51 gene and application of the toxoplasma gondii attenuated strain, and belongs to the technical field of gene engineering. A Tgsrs51 gene is deleted in a genome of the toxoplasma gondii attenuated strain; and the ID (Identity) number of the Tgsrs51 gene on a ToxoDB (Database) website is TGME49308840. A Tgsrs51 gene deleted strain of a toxoplasma gondii type II Pru strain is constructed by utilizing a CRISPR-Cas9 technology, and experiments prove that the Tgsrs51 gene deletion can remarkably reduce the invasion efficiency of the toxoplasma gondii Pru strain, the secretion capacity of micronematosome MIC2 and the tachyzoite proliferation rate, lead to in-vitro growth limitation, remarkably improve the survival rate of infected mice and remarkably reduce the number of intracerebral cysts. The invention provides a theoretical basis for researching a molecular mechanism and an immune mechanism of toxoplasma gondii pathopoiesis, and provides a new strategy for prevention and control of toxoplasmosis.

The invention is suitable for the technical field of cell separation and culture, and provides a pig nasal mucosa epithelial cell separation and culture method. A mixed enzyme overnight digestion method is adopted, mucous membrane tissue mucus is effectively removed, and more complete digestion is achieved. The pig nasal mucosa epithelial cells with relatively high purity are obtained through a differential attachment technology. And the culture medium is replaced by a complete culture medium containing EGF and vitamin A during first liquid replacement, so that a stable and excellent in-vitro growth environment is provided for epithelial cells. The method not only can rapidly and accurately separate the primary cells, but also ensures the stability and high quality of the culture state of the epithelial cells. According to the method, the blank of porcine nasal mucosa primary cell separation research is filled up, the primary porcine nasal mucosa epithelial cell in-vitro model which is simple and easy to implement and high in repeatability is constructed, and the model can simulate physiological and morphological characteristics of porcine nasal mucosa and can be used for preparing the porcine nasal mucosa epithelial cell in-vitro model. And a reliable in-vitro experimental basis is provided for researches on respiratory tract pathogen infection mechanisms, respiratory system disease drug screening, gene therapy and the like.

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and / or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and / or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and / or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.

Embodiments described herein relate generally to devices, apparatuses, and systems with embedded electrodes for growing, maintaining, and / or using 3D tissues in vitro. The devices, apparatuses, and systems described herein can provide scalable, automated tissue stimulation.

This invention provides a monoclonal antibody 4D5 against Rv0340 that can improve drug resistance in Mycobacterium tuberculosis. The heavy chain variable region of antibody 4D5 has the following amino acid sequences: CDR-H1 (SEQ ID No. 1), CDR-H2 (SEQ ID No. 2), and CDR-H3 (SEQ ID No. 3); and the light chain variable region of anti-Rv0340 monoclonal antibody 4D5 has the following amino acid sequences: CDR-L1 (SEQ ID No. 4), CDR-L2 (SEQ ID No. 5), and CDR-L3 (SEQ ID No. 6). This anti-Rv0340 monoclonal antibody 4D5 was prepared using Rv0340 protein as an antigen, and the effect of the anti-Rv0340 monoclonal antibody on the in vitro growth of Mtb in the presence of anti-tuberculosis drugs was investigated. The results showed that antibody 4D5 could significantly increase the sensitivity of Mtb to isoniazid; and when antibody 4D5 was used in combination with isoniazid, the survival rate of Mtb decreased by 26.58%. This invention provides a new monoclonal antibody drug for specifically improving the sensitivity of Mtb to isoniazid, and has the prospect of application as a monoclonal antibody drug to improve the drug resistance of Mycobacterium tuberculosis.

The invention discloses an application of LINC02568 as a target in preparation of an ER < + > breast cancer treatment kit. The reagent targeting LINC02568 can effectively inhibit in-vitro growth of ER < + > breast cancer cells and in-vivo tumor formation, and can be combined with an endocrine therapeutic drug or a small-molecule inhibitor targeting CA12 to achieve a synergistic inhibition effect on growth of cells and tumors.

Method for evaluating the growth dynamics of a human hair or hair Method for evaluating ex vivo the growth dynamics of at least one human hair or hair, having a hair follicle (1), the method comprising the steps of: imaging the hair follicle (1), placed in a culture medium (5), with an imager (2, 12, 28) for a sufficiently long observation period, with a sufficiently fast acquisition frequency, and a sufficiently fine resolution where appropriate, to obtain at least one animated sequence (9) of the growth of the hair or hair in this culture medium (5), making it possible in particular to observe movements of cells constituting the hair follicle, generating from this sequence (9) at least one piece of information relating to the growth dynamics of the hair or hair. Figure: 1

The invention relates to a murine triple-negative breast cancer high-metastasis cell line and application thereof, and belongs to the technical field of biological medicine. According to the invention, a breast cancer high-metastasis cell E0771 M-8 is screened by using a murine triple negative breast cancer cell line E0771, and is preserved in the China General Microbiological Culture Collection Center on March 12, 2025, and the preservation number is CGMCC NO.46331. The invention further discloses a preparation method of the breast cancer high-metastasis cell E0771. A cell function experiment shows that the in-vitro growth capability, the multiplication capability and the migration capability of the E0771 M-8 cell are enhanced; a mouse tumor-bearing experiment shows that the lung metastasis capability of the E0771 M-8 cell is enhanced. The highly metastatic breast cancer cell E0771 M-8 obtained by the invention provides a usable biological material for deeply researching a molecular mechanism of breast cancer metastasis and developing related antitumor drugs, and has relatively high scientific research and clinical application values.

To provide a biological treatment for intervertebral discs that can aid in repairing or replacing a subject's intervertebral disc.SOLUTION: The present invention relates to discogenic cell populations, methods of deriving the same, and methods of using the same. The discogenic cell population includes at least one cell derived from mammalian disc tissue and grown in vitro in anchorage-independent culture. The discogenic cell populations may be used to restore or regenerate damaged, diseased, or missing intervertebral discs of a subject. The discogenic cell populations can be derived from and administered or implanted into a subject, or may be derived from an unrelated donor.SELECTED DRAWING: None

A synthetic meat product for human and animal consumption and methods for producing such food product are disclosed. The synthetic food product comprises or essentially consists of a cell biomass of avian cells grown in vitro in a chemically-defined serum free culture medium under controlled conditions and do not contain ant hazard contaminations.

The invention relates to the technical field of tissue culture, in particular to an oocyte culture method and application thereof. The invention provides a culture method of oocytes. The culture method comprises the following steps: S10, providing oogonocytes; s20, carrying out hanging drop culture on the oogonium to obtain a recombinant ovary; and S30, carrying out suspension culture on the recombinant ovary to obtain the oocyte. According to the technical scheme provided by the invention, after the oogonium is cultured into the recombinant ovary through hanging drop culture, suspension culture is carried out, so that the oogonium in the recombinant ovary is differentiated into the oocyte, and the hanging drop culture and the suspension culture can reduce the situation of adherent growth of the oogonium or the oocyte; natural arrangement and interaction of the cells in vivo are simulated, so that a better in-vitro growth and differentiation environment is provided for the cells; moreover, relatively frequent digestion passage for contact inhibition between the cells is not needed in the hanging drop culture and suspension culture processes, so that the damage to the cells is smaller.

This invention discloses a small peptide protein that promotes the in vitro growth of rice pollen tubes, its expression method, and its application, belonging to the field of biotechnology. The small peptide protein for promoting the in vitro growth of rice pollen tubes in this invention is THION22, and its amino acid sequence is shown in SEQ ID No. 2. The expression method of this small peptide protein is as follows: the rice THION22 gene is cloned, transformed and expressed in *E. coli* to obtain a recombinant vector, and the obtained recombinant vector is used for the expression and purification of the small peptide protein. This invention applies THION22 small peptide protein to promote the in vitro growth of rice pollen tubes, specifically by collecting rice pollen grains from dehiscent anthers, transferring the pollen grains to a liquid culture medium containing THION22 small peptide protein, and culturing them under humid conditions in the dark. This invention, by applying THION22 small peptide protein in vitro to the liquid culture medium for rice pollen germination, can prolong the pollen tube rupture time, promote pollen tube growth, and maintain the integrity of the pollen tubes, which has important application value for rice hybridization breeding.

The application discloses tumor-related fibroblasts which can be targeted to die, the tumor-related fibroblasts carry polynucleotide fragments of sequences such as SEQ ID No:1 in chromosomes, and the tumor-related fibroblasts have morphology and in-vitro growth rate comparable to other tumor-related fibroblasts.The tumor-related fibroblasts can be specifically induced to die by drugs when co-cultured with other tumor-related fibroblasts, and the drugs are ganciclovir, and the ganciclovir drug concentration ranges from 1 to 100 μM.The application provides a novel and convenient cell construction method for studying the functions of different subtypes of CAFs and application thereof, and the novel CAFs can be targeted to die under the treatment of ganciclovir, weaken the effect of the CAFs of the type on co-cultured tumor cells, and help effectively distinguish the roles of different subtypes of CAFs in tumor occurrence and development.

The invention relates to a stable amorphous calcium carbonate as a cell culture medium supplement. A stable amorphous calcium carbonate (ACC) as a supplement for cell culture media and a cell culture media supplement comprising the stable ACC are provided. In particular, the stabilized ACC may be used to promote in vitro growth of cell and tissue cultures, gametes and embryos.

The application discloses a Cryptosporidium parvum CpDHR1 gene replacement strain and a construction method and application thereof. The application researches and finds that the CpDHR1 gene of Cryptosporidium parvum is related to virulence, the CpDHR1 gene of a high-virulence strain is replaced by the CpDHR1 gene of a low-virulence strain through a gene editing technology, and a Cryptosporidium parvum CpDHR1 gene replacement strain is successfully constructed. Research shows that after the CpDHR1 gene of a high-virulence wild-type Cryptosporidium parvum IIdA20G1 subtype strain is replaced, the strain can still be cultured in vitro, but the in-vitro growth of the strain is significantly reduced, the virulence of the strain is weakened, the oocyst excretion intensity of the strain is weakened, the oocyst load in mice is reduced, the clinical symptoms of the mice are alleviated, the survival time of the mice is prolonged, the virulence of the strain is significantly weakened, the strain can be used for preparing a Cryptosporidium parvum low-virulence vaccine product, and Cryptosporidium parvum infection can be better prevented.

The present application describes a large scale process for the in vitro production of an olive cell culture.The application further describes a composition in a form of a powder comprising olive fruit / leaf cells grown in vitro and a method of treating metabolic syndrome disorders, such as, high cholesterol level, comprising administering an effective amount of the composition. The cell line callus culture of olive cells manufactured according to the process of the invention includes high level of hydroxytyrosol, tyrosol, oleuropein and verbascoside.

The invention discloses application of a rhizoma coptidis aqueous extract in preparation of biopesticide for inhibiting melanospora, and belongs to the field of biopesticide application of rhizoma coptidis aqueous extracts and monomers thereof. The in-vitro inhibition effect of the rhizoma coptidis aqueous extract and the monomer thereof on the melanospora nigra is researched by adopting an in-vitro model of the melanospora nigra. An in-vitro growth rate method finds that the rhizoma coptidis aqueous extract and a monomer thereof have a remarkable inhibition effect on melanospora sp. Experimental results show that the rhizoma coptidis aqueous extract or the rhizoma coptidis monomeric compound has an exact effect of inhibiting the melanospora nigra and can be applied to preparation of biopesticides for inhibiting the melanospora nigra.

The invention discloses a gatF gene knockout bovine pasteurella multocida attenuated strain as well as a construction method and application thereof, and belongs to the technical field of gene engineering and biology. The attenuated strain is obtained by knocking out a gatF gene in pasteurella multocida through a homologous recombination method. The strain is stable in heredity, the in-vitro growth characteristic is the same as that of a wild strain, but the toxicity to mice is obviously weakened. Animal tests show that after mice are immunized by the low virulent strain, high-level specific antibodies can be induced to be generated, and up to 80% of immune protection can be provided for attack of the high virulent strain. The invention provides a safe and effective candidate vaccine strain for preventing pasteurellosis multocida, particularly bovine respiratory disease syndrome caused by L3 type strains.

The present invention belongs to the field of biotechnology and discloses a recombinant turkey herpes virus expressing the VP2 gene of a new variant of infectious bursal disease virus. The virus is obtained by inserting a target gene into the HVT065 site of the UL region of the turkey herpes virus. The target gene is a VP2 gene with a promoter and a terminator. The VP2 gene is derived from a currently prevalent new variant of infectious bursal disease virus. The present invention discloses the nucleotide sequence of the VP2 gene (SEQ ID NO.1) and the amino acid sequence of a VP2 protein (SEQ ID NO.2). The recombinant virus provided by the present invention has the same in vitro growth and replication ability as the parent virus HVT and can provide good immune protection for the new variant of infectious bursal disease virus. In addition, the present invention discloses a VP2 gene, a target gene, a VP2 protein and its use.